AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
IDEXX's (IDXX) Soft LPD Sales, Margin Pressure Concern
by Zacks Equity Research
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) CAG segment product sales.
Will Defensive Sectors Shine in the Extremely Volatile 2022?
by Nalak Das
We have narrowed our search to five defensive stocks. These are: GWRS, VST, AMN, ADM, PPC.
Shockwave Medical's (SWAV) IVL Cleared for Use in China
by Zacks Equity Research
Shockwave Medical's (SWAV) latest regulatory approval is expected to serve a wider patient pool.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
Thermo Fisher (TMO) to Advance Precision Medicine in Qatar
by Zacks Equity Research
Thermo Fisher's (TMO) collaboration with Qatar Genome Program will utilize the power of genomics to enhance the standard of healthcare for the Qatari population.
Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger
by Zacks Equity Research
Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.
Here's Why Investors Should Retain Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
by Zacks Equity Research
The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
Catalent's (CTLT) Latest Facility Expansion to Boost Capacity
by Zacks Equity Research
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.
AMN Healthcare (AMN) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Align Technology (ALGN) Debuts Invisalign Outcome Simulator Pro
by Zacks Equity Research
The next-generation of Align Technology's (ALGN) advanced patient communication tool will help patients see their potential new smile after Invisalign treatment.
Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.
PerkinElmer (PKI) Boosts Genomic Testing Portfolio With urWGS
by Zacks Equity Research
PerkinElmer's (PKI) urWGS will improve outcomes for critically ill patients in NICUs and PICUs.
Catalent's (CTLT) New Launch to Enhance Gene Therapy Development
by Zacks Equity Research
Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.
Globus Medical (GMED) Completes First Cases With Excelsius3D
by Zacks Equity Research
Globus Medical's (GMED) Excelsius3D, when combined with ExcelsiusGPS, facilitates greater implant placement accuracy, lowers radiation exposure and reduces operative times.
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
Here's Why Investors Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) better-than-expected results and robust segmental growth.
QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio
by Zacks Equity Research
The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.
NextGen Healthcare (NXGN) Q4 Earnings Miss Mark, Revenues Beat
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal fourth-quarter earnings reflect strength in its Recurring revenues.
BD (BDX) Introduces New Molecular Diagnostic Platform in US
by Zacks Equity Research
BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Reasons to Add Patterson Companies (PDCO) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) better-than-expected revenues and robust performance across several geographies.